Previous 10 | Next 10 |
OPKO Health, Inc. (OPK) Q4 2021 Earnings Conference Call February 24, 2022 04:30 PM ET Company Participants Yvonne Briggs - Investor Relations Phillip Frost - Chairman & Chief Executive Officer Steve Rubin - Executive Vice President Jon Cohen - Managing Director, Executive Chairman of Bio...
OPKO Health (NASDAQ:OPK), a healthcare company focused on diagnostics and pharmaceuticals, is trading ~10% lower in the post-market Thursday after indicating a mixed performance with its Q4 2021 results amid falling COVID-19 testing volumes. Revenue for the quarter dropped ~19% YoY ...
OPKO Health press release (NASDAQ:OPK): Q4 GAAP EPS of -$0.11 misses by $0.09. Revenue of $401.3M (-18.9% Y/Y) beats by $84.04M. Revenue from services in the fourth quarter of 2021 were to $362.8M compared to $457.9M in the prior-year period. Revenue from products in the fourth quarter of 202...
MIAMI, Feb. 24, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2021. Business Highlights Business highlights for the fourth quarter of 2021 and subsequent weeks include the ...
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financial markets on Thursday, February 24, 2022. OPKO’s senior management will provid...
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and ad...
The big story in the stock market today: Facebook Meta stock . Shares of the tech company fell to levels not seen since the summer of 2020. Even with the pullback in broader markets, Meta Platforms ( NASDAQ:FB ) struggled to reclaim early 2022 prices as uncertainty arose thanks ...
OPKO Health (OPK +5.3%) trades higher following the company's CEO & Chairman bought 150,000 shares at $2.99 - $3.05 worth ~ $460K. For further details see: OPKO Health rises 5% as CEO & Chairman buys 1.5M shares
Opko Health (OPK +5.1%) said Vifor Fresenius Medical Care Renal Pharma launched Rayaldee (extended release calcifediol) in Germany. Rayaldee extended-release capsules are indicated for treating secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease ...
MIAMI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE ® (extended release calcifediol) in Germany, the first launch of RAYALDEE outside the U.S. ...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common ...
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relat...
NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner PR Newswire New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additi...